Ultragenyx Pharmaceutical, Inc. ( (RARE) ) has released its Q4 earnings. Here is a breakdown of the information Ultragenyx Pharmaceutical, Inc. presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company specializing in the development and commercialization of therapies for rare and ultra-rare genetic diseases. In its latest earnings report, Ultragenyx announced a total revenue of $560 million for 2024, surpassing its guidance, with significant contributions from its products Crysvita and Dojolvi. The company provided 2025 financial guidance, projecting total revenue between $640 million and $670 million.
Key financial metrics highlighted a 29% revenue growth year-over-year, with Crysvita generating $410 million and Dojolvi contributing $88 million in 2024. Despite the revenue growth, Ultragenyx reported a net loss of $569 million for the year, an improvement from the $606 million loss in 2023. The company remains focused on strategic projects, including several Phase 3 clinical trials and pending regulatory decisions.
Strategically, Ultragenyx is advancing its pipeline with several key programs, such as the Phase 3 trials for osteogenesis imperfecta and Angelman syndrome. They are also preparing for potential launches of gene therapies for Sanfilippo syndrome and Glycogen Storage Disease Type Ia. In 2025, significant milestones include the anticipated PDUFA decision for UX111 and the completion of enrollment for UX701 in Wilson Disease.
Looking forward, Ultragenyx remains committed to expanding its therapeutic portfolio and progressing towards profitability. The management emphasized their focus on cost management and strategic investments in upcoming commercial launches and clinical programs. The company aims to reduce net cash used in operations in 2025 while achieving projected revenue growth.
